Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Consolidated Net Income (2022 - 2026)

Zentalis Pharmaceuticals has reported Consolidated Net Income over the past 5 years, most recently at -$35.4 million for Q1 2026.

  • For Q1 2026, Consolidated Net Income rose 26.78% year-over-year to -$35.4 million; the TTM value through Mar 2026 reached -$124.1 million, up 44.63%, while the annual FY2025 figure was -$137.1 million, 17.37% up from the prior year.
  • Consolidated Net Income for Q1 2026 was -$35.4 million at Zentalis Pharmaceuticals, roughly flat from -$35.2 million in the prior quarter.
  • Over five years, Consolidated Net Income peaked at $10.0 million in Q1 2024 and troughed at -$98.9 million in Q2 2023.
  • A 5-year average of -$49.1 million and a median of -$48.3 million in 2025 define the central range for Consolidated Net Income.
  • Biggest five-year swings in Consolidated Net Income: surged 116.47% in 2024 and later crashed 580.87% in 2025.
  • Year by year, Consolidated Net Income stood at -$48.2 million in 2022, then dropped by 26.53% to -$60.9 million in 2023, then rose by 22.1% to -$47.5 million in 2024, then increased by 25.82% to -$35.2 million in 2025, then dropped by 0.39% to -$35.4 million in 2026.
  • Business Quant data shows Consolidated Net Income for ZNTL at -$35.4 million in Q1 2026, -$35.2 million in Q4 2025, and -$26.7 million in Q3 2025.